Pioneering science
to transform patient outcomes

Annual Report 2023

scroll for more

Dr. Paul Stoffels, CEO and Chairman

Group net revenues

€ 783.5

million

Cash position

€ 3,684.5

million

Deferred income

€ 1,327.5

million

R&D expenditure

€ 431.5

million